Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Proposed US BIOSECURE Act - Do Lonza, Other CDMOs Gain And How Soon?

Indian Companies Expect Tailwinds

Executive Summary

Concerns over the impact of the proposed US BIOSECURE Act on the CRO and CDMO segments linger despite proponent Mike Gallagher’s plan to leave Congress soon. Which global manufacturers could gain, what determines a shift away from Chinese companies and how imminent is this? Scrip brings insights from industry feedback and other sources.

You may also be interested in...



Novo Reaches Winning Post With Gamechanger Once-Weekly Insulin

The Danish drugmaker is cementing its leadership in diabetes with an imminent approval in Europe for Awiqli which reduces the number of basal insulin injections for patients from seven to just one per week.

China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes

The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.

WuXi AppTec Quits BIO As Group Endorses BIOSECURE Act

BIO chairman Ted Love had said at BIO CEO last month that “damaging” the company could have unintended consequences.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC150017

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel